Dataset from The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in Nonalcoholic Steatohepatitis (NASH) Treatment (FLINT) Trial
收藏NIAID Data Ecosystem2026-05-10 收录
下载链接：
https://doi.org/10.25934/PR00008507
下载链接
链接失效反馈官方服务：
资源简介：
Administration of the farnesoid X receptor (FXR) ligand obeticholic acid (OCA) for 72 weeks
to subjects with biopsy evidence of nonalcoholic steatohepatitis (NASH) will result in
improvement in their liver disease as measured by changes in the nonalcoholic fatty liver
disease (NAFLD) activity score (NAS).
创建时间：
2026-02-06
